Your selection

Innovation / 07.05.2020
Eckert & Ziegler Enters TecDAX

The Berlin-based Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, S-DAX) a specialist in isotope-related applications in medicine, science and industry, will enter the TecDAX effective as of 8 May 2020.

This index, which is measured in terms of market capitalisation of the free float and trading volume in the shares, comprises the 30 largest technology stocks in Germany.

"We are pleased about the admission to the TecDAX and expect that this will give our company and our share additional attention on the international capital market. Thanks to its strong growth, Eckert & Ziegler is now officially one of the largest listed technology companies in Germany," said Dr. Andreas Eckert, Chief Executive Officer of Eckert & Ziegler AG.

About Eckert & Ziegler.
Eckert & Ziegler Eckert & Ziegler Strahlen- und Medizintechnik AG with around 800 employees, is one of the world's largest providers of isotope-related components for radiation therapy and nuclear medicine.

www.ezag.de

Overview News

News Buch Berlin

Eckert & Ziegler: Seed Implantation for Prostate Cancer Receives Reimbursement for Outpatient Care

Seed implantation for prostate cancer is now to be reimbursed as an outpatient treatment by public health insurances in Germany. This was decided by the Federal Joint Committee (G-BA) with effect from...

more ...

Enhanced speed, contrast, and information: New contrast mechanism improves xenon MRI

Xenon magnetic resonance imaging offers deep insights into the human body and opens up new possibilities in the diagnosis and treatment of diseases.

more ...

A potent weapon against lymphomas

MDC researchers have developed a new approach to CAR T-cell therapy. The team has shown in Nature Communications that the procedure is very effective, especially when it comes to fighting follicular l...

more ...

Events Buch Berlin

14.09.2021, 09:00
GMP Biotech Summer School

Good Manufacturing Practice (GMP) Basic Course Biotechnology (English)

more ...

This website is supported by: